Financings Of The Fortnight: VC Double-Down Investments Aren't Last-Gasp Hopes
This article was originally published in The Pink Sheet Daily
Executive Summary
Two recent financings in which VC firms reinvested in private biotechs were led by cash-flush European investors.
You may also be interested in...
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
With funds and firms closing, a new reality awaits those who survive until the next economic upswing. Some of the elements are already in place, such as VCs' willingness to take capped returns and exits via risk-sharing contingency-based acquisitions. The emphasis on capital efficiency may change the types of companies VCs can afford to back, and corporate funds are now a vital part of biotech venture, especially in the early stages.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.